They detect tumor antigens by detecting MHC class I deficiencies in tumor cells or via the uptake of antigens by dying tumor cells, which activates CD4+ T cells via the T-cell receptor (TCR), CD28, and B-cell responses. This evidence concerns the gene CD28 and neoplasm.